上QQ阅读APP看书，第一时间看更新
参考文献
1.吴孟超．原发性肝癌诊疗规范（2017年版）．临床肝胆病杂志，2017，33（08）：1419-1431.
2.Omata M. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma：a 2017 update. Hepatology international，2017，11（4）：317-370.
3.Lee JM，Park J，Choi BI. 2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma：HCC Diagnostic Algorithm. Digestive Diseases，2014，32（6）：764-777.
4.Kudo M. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma：2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer，2014，3（3-4）：458-468.
5.Benson AR. NCCN Guidelines Insights：Hepatobiliary Cancers，Version 1.2017. J Natl Compr Canc Netw，2017，15（5）：563-573.
6.Bruix J，Sherman M. Management of hepatocellular carcinoma：an update. Hepatology，2011，53（3）：1020-1022.
7.Heimbach JK. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology，2018，67（1）：358-380.
8.EASL Clinical Practice Guidelines：Management of hepatocellular carcinoma. J Hepatol，2018，69（1）：182-236.
9.李若坤，严福华．肝细胞癌国际诊断指南与国内诊疗规范的比较与解读．中华放射学杂志，2018，52（9）：725-728.
10.饶圣祥．肝胆特异性MRI对比剂钆塞酸二钠临床应用专家共识．临床肝胆病杂志，2016，32（12）：2236-2241.
11.Hamm B. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent：safety，pharmacokinetics，and MR imaging. Radiology，1995，195（3）：785-792.
12.Huppertz A. Improved detection of focal liver lesions at MR imaging：multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology，2004，230（1）：266-275.
13.Hammerstingl R. Diagnostic efficacy of gadoxetic acid（Primovist）-enhanced MRI and spiral CT for a therapeutic strategy：comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol，2008，18（3）：457-467.
14.Haradome H. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of earlystage hepatocellular carcinoma：comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging，2011，34（1）：69-78.
15.Yoo SH. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma. Ann Surg Oncol，2013，20（9）：2893-2900.
16.Zech CJ. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg，2014，101（6）：613-621.